Studying Early Use of Tranexamic Acid to Reduce Blood Loss During Surgery for Adult Hip Fracture Patients

What this Trial Is About

Researchers are evaluating the effect of early administration of tranexamic acid TXA on blood loss in adults with intracapsular and extracapsular hip fractures undergoing surgery. The study aims to assess whether giving TXA as soon as possible after diagnosis, in addition to the usual intraoperative dose, reduces perioperative blood loss and the need for postoperative blood transfusions. This investigation is conducted at a Level II trauma center and is sponsored by Ascension Health. The study has two groups one group receives 1 gram of TXA soon after diagnosis plus an additional gram during surgery, totaling 2 grams the other group receives only the intraoperative dose of 2 grams. TXA is given intravenously, with one dose infused before incision and the other at wound closure. Participants are randomly assigned to one of these groups to compare outcomes. Participants will be monitored for up to two weeks after surgery to measure outcomes like overall blood loss, need for blood transfusions, length of hospital stay, postoperative pain, wound complications, and occurrence of acute deep vein thrombosis or pulmonary embolism. The study involves assessments during hospital stay and follow-up to track these measures and ensure participant safety.

Effect of Early Administration of TXA in Adult Hip Fractures